Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States

15 April 2024

Harrison W. Farber, Hayley D. Germack, Nicole S. Croteau, Jason C. Simeone, Fei Tang, Carly J. Paoli, Gurinderpal Doad, Sumeet Panjabi, Teresa De Marco

https://doi.org/10.1002/pul2.12326

Abstract 

Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.

Read the full research letter

Share:

Other materials on this topic

Additional comments are available to members. Login or register to become a member today
RegisterorLogin to view

More from Pulmonary Circulation

Show more details

A collection of up-to-date abstracts from our premier, international, peer-reviewed, medical research journal dedicated exclusively to pulmonary circulation and pulmonary vascular disease. 

Pulmonary vascular disease, environmental pollution, and climate change
Human pulmonary microvascular endothelial cells respond to DAMPs from injured renal tubular cells
Creating a digital approach for promoting physical activity in pediatric pulmonary hypertension: A framework for future interventions
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary disease without pulmonary hypertension
A systematic review of the impact of pulmonary thromboendarterectomy on health-related quality of life
Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH): A global cross-sectional scientific survey (CLARITY)
Ruptured pulmonary arteriovenous fistula causing hemothorax in a patient with hereditary hemorrhagic telangiectasia: A case report
A perfectly imperfect engine: Utilizing the digital twin paradigm in pulmonary hypertension
Nonsurgical treatment of a patient with decompensated right ventricular failure due to chronic thromboembolic pulmonary hypertension with proximal clot location—A case report
The European Voice of the Patient living with pulmonary hypertension associated with interstitial lung disease: Diagnosis, symptoms, impacts, and treatments
Excess healthcare resource utilization and costs for commercially insured patients with pulmonary arterial hypertension: A real-world data analysis
Demographic, hemodynamic characteristics, and therapeutic trends of pulmonary hypertension patients: The Pulmonary Hypertension Mexican registry (REMEHIP)
Cardiopulmonary exercise testing and the 2022 definition of pulmonary hypertension
Association of mildly elevated pulmonary vascular resistance with major cardiovascular events in pulmonary hypertension and chronic kidney disease: A retrospective cohort analysis
Evaluating the technical use of a Fitbit during an intervention for patients with pulmonary arterial hypertension with quality of life as primary endpoint: Lessons learned from the UPHILL study